Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study
- 4 Downloads
We aimed to determine whether tumor necrosis factor inhibitors (TNFi) have beneficial effects on bone mineral density (BMD) in rheumatoid arthritis (RA) patients with osteoporosis receiving bisphosphonate. A total of 199 RA patients, who were newly diagnosed with osteoporosis and receiving bisphosphonate between January 2005 and March 2017, were reviewed. Changes in BMD after 1 year were compared between patients treated with and without TNFi. The inverse probability of treatment weighting (IPTW) method using the propensity score was performed to minimize confounding factors, and logistic regression analysis was applied to identify any factors associated with significant BMD improvement (≥ 3%) at the lumbar spine and femur neck. Among patients receiving bisphosphonate, 29 were exposed to TNFi, and 170 patients were not exposed. The percentage change in BMD and the proportion of significant improvements at the lumbar spine and femur neck were similar between patients treated with and without TNFi, before and after IPTW adjustment. In addition, the disease activity score 28 (DAS28) with three variables [adjusted odds ratio (OR) 0.741, 95% confidence interval (CI) 0.592–0.927, p = 0.009] and cumulative steroid dose (adjusted OR 0.639, 95% CI 0.480–0.851, p = 0.002) were inversely associated with an improvement in BMD. Conversely, TNFi use was not associated with any improvement in BMD after adjustment by IPTW using the propensity score. TNFi did not influence BMD improvement in RA patients with osteoporosis receiving bisphosphonate, suggesting that TNFi cannot be considered as a preferred therapeutic option for increasing BMD.
KeywordsOsteoporosis Rheumatoid arthritis Diphosphonate Tumor necrosis factor Antibodies Monoclonal
The authors would like to thank Enago (http://www.enago.co.kr) for their language editing and we also thank Dr. Min Kyu Han (Departments of Clinical Epidemiology, Biostatistics, Asan Medical Center) for providing statistical support.
Conceptualization and design of study: DHL, BY, and SH. Data collection: JSL and DHL. Statistical analysis: JSL and DHL. Data interpretation: JSO, YGK, CKL, BY, and SH. Manuscript preparation: JSL, DHL, and SH. Manuscript revision: JSL, YGK, CKL, BY, and SH. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
The research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
This study complied with the recommendations of the Declaration of Helsinki and was approved by the Institutional Review Board of the Asan Medical Center (2018-08-08/Approval number 2018-0946).
- 4.Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275–286. https://doi.org/10.1084/jem.191.2.275 CrossRefGoogle Scholar
- 6.Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499. https://doi.org/10.1136/ard.2005.044198 CrossRefGoogle Scholar
- 9.Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:R61. https://doi.org/10.1186/ar2219 CrossRefGoogle Scholar
- 10.Yasunori K, Masaaki T, Tetsuyuki N, Hayato K, Akira N (2008) Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol 27:1093–1101. https://doi.org/10.1007/s10067-008-0870-8 CrossRefGoogle Scholar
- 14.Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581. https://doi.org/10.1002/art.27584 CrossRefGoogle Scholar
- 18.Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Anno S, Koike T (2017) Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study. Rheumatol Int 37:999–1005. https://doi.org/10.1007/s00296-017-3720-7 CrossRefGoogle Scholar
- 19.Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA (2006) Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 17:716–723. https://doi.org/10.1007/s00198-005-0037-2 CrossRefGoogle Scholar
- 20.Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM, Marchandise X, Delcambre B (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 18:683–690Google Scholar
- 21.O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841. https://doi.org/10.1210/en.2003-0990 CrossRefGoogle Scholar
- 23.Okano T, Koike T, Tada M, Sugioka Y, Mamoto K, Wakitani S, Nakamura H (2014) The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid. J Bone Miner Metab 32:593–600. https://doi.org/10.1007/s00774-013-0535-9 CrossRefGoogle Scholar
- 24.Tawaratsumida H, Setoguchi T, Arishima Y, Ohtsubo H, Akimoto M, Ishidou Y, Nagano S, Taketomi E, Sunahara N, Komiya S (2017) Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. BMC Res Notes 10:765. https://doi.org/10.1186/s13104-017-3086-7 CrossRefGoogle Scholar
- 25.Maricic M, Deal C, Dore R, Laster A (2018) 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis: comment on the article by Buckley et al. Arthritis Care Res (Hoboken) 70:949–950. https://doi.org/10.1002/acr.23424 CrossRefGoogle Scholar